Codex_V5

Drew WL

References:

Rank: 3 - A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.(Dec 2000)
Rank: 5 - Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.(Jul 2003)
Rank: 5 - Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.(Feb 2007)
Rank: 7 - Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.(Jan 2002)
Rank: 8 - Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.(Sep 1997)

Mutations:

Mutant	Gene	Virus	Reference
D301N	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
D301N	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
D301N	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
N410K	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
N410K	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
N410K	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
F412C	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
F412C	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
F412C	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
D413E	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
D413E	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
D413E	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
D413A	UL54	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
D413A	UL54	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
D413A	UL54	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
T503I	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
T503I	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
T503I	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
L516R	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
L516R	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
L516R	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756D	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756D	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756D	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756K	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756K	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756K	UL54	Human betaherpesvirus 5	Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
L802M	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
L802M	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
L802M	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
D981del	UL54	Human betaherpesvirus 5	A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
D981del	UL54	Human betaherpesvirus 5	A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
D981del	UL54	Human betaherpesvirus 5	A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
D329H	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
591-607del	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
A594E	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
E596G	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
601-602del	UL97	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
601-603del	UL97	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)

CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database

Drew WL

Mutations: